CSL Limited (CSL.AX)
- Previous Close
271.40 - Open
270.01 - Bid 269.00 x 13700
- Ask 269.99 x 21700
- Day's Range
265.14 - 270.65 - 52 Week Range
228.65 - 312.99 - Volume
1,424,892 - Avg. Volume
714,506 - Market Cap (intraday)
130.232B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
34.11 - EPS (TTM)
7.90 - Earnings Date Feb 13, 2024
- Forward Dividend & Yield 3.81 (1.41%)
- Ex-Dividend Date Mar 11, 2024
- 1y Target Est
303.61
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
www.csl.com.auRecent News: CSL.AX
![CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])](https://s.yimg.com/uu/api/res/1.2/LarevtbpZXYX_jIs8G5JQA--~B/Zmk9ZmlsbDtoPTYzO3B5b2ZmPTA7dz04NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/f57d6417ee02a6b52d9a87c500485e01.cf.webp)
Performance Overview: CSL.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CSL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CSL.AX
Valuation Measures
Market Cap
130.23B
Enterprise Value
147.45B
Trailing P/E
34.09
Forward P/E
30.03
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.00
Price/Book (mrq)
4.88
Enterprise Value/Revenue
10.51
Enterprise Value/EBITDA
33.62
Financial Highlights
Profitability and Income Statement
Profit Margin
17.43%
Return on Assets (ttm)
6.41%
Return on Equity (ttm)
13.63%
Revenue (ttm)
14.18B
Net Income Avi to Common (ttm)
2.47B
Diluted EPS (ttm)
7.90
Balance Sheet and Cash Flow
Total Cash (mrq)
1.02B
Total Debt/Equity (mrq)
63.18%
Levered Free Cash Flow (ttm)
692.8M